Real-time Estimate
Cboe BZX
11:39:40 2024-06-10 am EDT
|
5-day change
|
1st Jan Change
|
1.175
USD
|
+10.85%
|
|
+5.96%
|
-10.47%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
422.7
|
215.6
|
133.2
|
203.2
|
144.9
|
153.5
|
-
|
-
|
Enterprise Value (EV)
1 |
422.7
|
215.6
|
133.2
|
203.2
|
144.9
|
153.5
|
153.5
|
153.5
|
P/E ratio
|
-3.51
x
|
-2
x
|
-1.12
x
|
-2.13
x
|
-4.03
x
|
-4.12
x
|
-13.7
x
|
10.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
12.2
x
|
4.39
x
|
1.78
x
|
2.66
x
|
2.04
x
|
1.67
x
|
1.13
x
|
0.91
x
|
EV / Revenue
|
12.2
x
|
4.39
x
|
1.78
x
|
2.66
x
|
2.04
x
|
1.67
x
|
1.13
x
|
0.91
x
|
EV / EBITDA
|
-4.99
x
|
-2.51
x
|
-2.02
x
|
-3.67
x
|
-6.48
x
|
-28.3
x
|
14.7
x
|
5.36
x
|
EV / FCF
|
-4.47
x
|
-2.49
x
|
-1.73
x
|
-
|
-
|
148
x
|
6.38
x
|
4.57
x
|
FCF Yield
|
-22.4%
|
-40.2%
|
-57.9%
|
-
|
-
|
0.68%
|
15.7%
|
21.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
45,842
|
52,081
|
82,200
|
109,840
|
112,312
|
144,839
|
-
|
-
|
Reference price
2 |
9.220
|
4.140
|
1.620
|
1.850
|
1.290
|
1.060
|
1.060
|
1.060
|
Announcement Date
|
3/5/20
|
3/3/21
|
3/8/22
|
3/7/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
34.63
|
49.12
|
74.65
|
76.28
|
70.99
|
91.77
|
135.3
|
169.6
|
EBITDA
1 |
-84.63
|
-85.76
|
-65.8
|
-55.36
|
-22.35
|
-5.417
|
10.48
|
28.64
|
EBIT
1 |
-95.6
|
-87.22
|
-66.45
|
-55.9
|
-22.75
|
-12.01
|
7.593
|
28.15
|
Operating Margin
|
-276.06%
|
-177.57%
|
-89.01%
|
-73.28%
|
-32.05%
|
-13.08%
|
5.61%
|
16.6%
|
Earnings before Tax (EBT)
1 |
-110.1
|
-99.79
|
-82.3
|
-74.83
|
-35.48
|
-32.21
|
-9.79
|
14.68
|
Net income
1 |
-110.1
|
-99.79
|
-82.3
|
-74.83
|
-35.48
|
-32.21
|
-9.79
|
13.66
|
Net margin
|
-317.79%
|
-203.16%
|
-110.24%
|
-98.11%
|
-49.99%
|
-35.1%
|
-7.24%
|
8.06%
|
EPS
2 |
-2.630
|
-2.070
|
-1.450
|
-0.8700
|
-0.3200
|
-0.2575
|
-0.0775
|
0.1000
|
Free Cash Flow
1 |
-94.59
|
-86.75
|
-77.1
|
-
|
-
|
1.039
|
24.06
|
33.57
|
FCF margin
|
-273.15%
|
-176.62%
|
-103.28%
|
-
|
-
|
1.13%
|
17.78%
|
19.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
229.62%
|
117.21%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
245.66%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
3/3/21
|
3/8/22
|
3/7/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
22.51
|
14.76
|
20.58
|
20.08
|
20.86
|
11.85
|
19.45
|
19.82
|
19.86
|
14.88
|
21.11
|
24.28
|
32.42
|
24.5
|
33.6
|
EBITDA
1 |
-11.5
|
-19.28
|
-
|
-
|
-8.224
|
-
|
-
|
-
|
-
|
-
|
-2.104
|
-0.632
|
3.435
|
-
|
-
|
EBIT
1 |
-11.67
|
-21.4
|
-15.34
|
-10.8
|
-8.356
|
-14.37
|
-4.172
|
-1.694
|
-2.512
|
-8.075
|
-4.904
|
-2.39
|
3.159
|
-3
|
1
|
Operating Margin
|
-51.84%
|
-144.95%
|
-74.56%
|
-53.79%
|
-40.07%
|
-121.29%
|
-21.45%
|
-8.55%
|
-12.65%
|
-54.27%
|
-23.24%
|
-9.85%
|
9.74%
|
-12.24%
|
2.98%
|
Earnings before Tax (EBT)
1 |
-15.62
|
-25.33
|
-19.4
|
-14.95
|
-15.15
|
-18.85
|
2.626
|
-9.294
|
-9.967
|
-14.07
|
-9.709
|
-7.178
|
-1.611
|
-7.7
|
-3.8
|
Net income
1 |
-15.62
|
-25.33
|
-19.4
|
-14.95
|
-15.15
|
-18.85
|
2.573
|
-9.294
|
-9.967
|
-14.07
|
-9.709
|
-7.178
|
-1.611
|
-7.7
|
-3.8
|
Net margin
|
-69.41%
|
-171.63%
|
-94.24%
|
-74.48%
|
-72.64%
|
-159.1%
|
13.23%
|
-46.88%
|
-50.17%
|
-94.54%
|
-46%
|
-29.57%
|
-4.97%
|
-31.43%
|
-11.31%
|
EPS
2 |
-0.2300
|
-0.3100
|
-0.2300
|
-0.1800
|
-0.1700
|
-0.1700
|
0.0200
|
-0.0800
|
-0.0900
|
-0.1200
|
-0.0767
|
-0.0600
|
-0.0133
|
-0.0600
|
-0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/8/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/7/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/7/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-94.6
|
-86.8
|
-77.1
|
-
|
-
|
1.04
|
24.1
|
33.6
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.56
|
0.55
|
0.17
|
0.06
|
0.33
|
0.33
|
0.41
|
0.41
|
Capex / Sales
|
1.61%
|
1.11%
|
0.22%
|
0.08%
|
0.46%
|
0.36%
|
0.31%
|
0.24%
|
Announcement Date
|
3/5/20
|
3/3/21
|
3/8/22
|
3/7/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
1.06
USD Average target price
3.75
USD Spread / Average Target +253.77% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.83% | 154M | | +45.82% | 765B | | -6.16% | 354B | | +19.86% | 331B | | +9.32% | 299B | | +18.79% | 248B | | -1.68% | 219B | | +11.11% | 216B | | +5.90% | 164B | | -0.73% | 162B |
Other Pharmaceuticals
|